Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > November 14, 2022
Daily News
November 14, 2022
- Teikoku’s Donepezil Tape, AbbVie’s Parkinson’s Med Up for PAFSC Review on Nov. 25
November 14, 2022
- Asian Regulatory Harmonization Underutilized by Japan Drug Makers, Priorities on Western Markets
November 14, 2022
- 2 Women Die after BA.5 COVID Booster Shots: MHLW
November 14, 2022
- Kokando Told to Suspend Business for Up to 36 Days over Decades-Long Violations
November 14, 2022
- GHIT Fund to Bankroll 790 Million Yen for Filariasis, Onchocerciasis
November 14, 2022
- Kyowa Kirin Files Romiplate for Aplastic Anemia in Japan
November 14, 2022
- Online Submissions for Generic Approval to Start from January
November 14, 2022
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…